The opioid epidemic is officially a public health emergency: Approximately 116 people die every day in the U.S from opioid-related drug overdoses. And the crisis shows no signs of decelerating despite millions of dollars earmarked for treatment programs—as well as increased monitoring requirements under which health care organizations like yours are obliged to report overdoses and deaths. One often overlooked obstacle to your effective participation in this monitoring is that federal regulations actually put you in a compliance Catch 22: Heed reporting requirements or records disclosure law?
42 C.F.R. Part 2—the Federal Confidentiality of Substance Use Disorder Patient Records (or Part 2) creates a barrier to effective care because it generally prohibits federally assisted substance use disorder programs from disclosing health information, without written patient consent, for the purposes of treatment, payment, health care operations and public health reporting. And Part 2 violations carry criminal penalties.
Join expert speaker Melissa Soliz as she breaks down a complex legal concept into a set of straightforward questions health care organizations can ask to determine Part 2 applicability and compliance obligations. Specifically, she will explain the Part 2 regulations’ consent requirements and how to identify and determine when an exception to those requirements is available. Soliz will also teach you how to structure a patient consent process that gives the patient’s treating providers and health plans access to important substance use disorder information.
After attending this audio event, you will be able to determine when your health care facility, a unit within that facility, or other personnel are a “Part 2 Program” under 42 C.F.R. Part 2. You’ll understand how to determine whether a patient’s substance use disorder information is protected by the regulations, and how to craft policies and procedures for the permissible disclosure of protected substance use disorder information. Finally, you’ll understand how to implement a process for the disclosure of protected substance use disorder information—without incurring penalties.
This webinar will reveal:
Who Should Attend
Ask a question at the Q&A session following the live event and get advice unique to your situation, directly from our expert speaker.
Melissa A. Soliz is a senior associate at Coppersmith Brockelman PLC in Phoenix, Arizona. The focus of her regulatory healthcare practice is on federal and state confidentiality laws (with an emphasis on 42 C.F.R. Part 2), data sharing for health information exchange and research, data breach reporting, regulatory compliance and contracting for human subjects research, Arizona licensing and scope of practice requirements, and other state and federal regulatory...
More Events By The Speaker